αααααβααΎαDBVT β’ NASDAQ
add
DBV Technologies SA - ADR
19.45$
αααααααααα(0.00%)0.00
19.45$
ααΆααα·αα 19 ααΈααΆ, 4:00:21 PM ααααβααα -4 · USD · NASDAQ · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·α
αα·αααΈαα»α
19.45$
α
αααααααααααα
18.93$ - 19.58$
α
ααααααα½αααααΆαα
α»αααααα
3.91$ - 26.19$
ααΎαβαα»αβααΈααααΆα
1.08Β αααΈααΆα USD
ααα ααα½αααΌαααααα
271.10Β ααΆαα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (EUR) | 2018info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 11.19Β ααΆα | 16.51% |
α
αααΆαααααα·ααααα·ααΆα | 177.41Β ααΆα | 14.76% |
α
αααΌααα»ααα | -166.08Β ααΆα | -12.45% |
ααααΆααα
αααααα»ααα | -1.48ααΆαα | 3.49% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | -57.40 | -380.74% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | -161.97Β ααΆα | -13.94% |
α’ααααΆαααααααααΆαααααα·αααααΆα | -0.01% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (EUR) | 2018info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 122.77Β ααΆα | -10.96% |
ααααααααα»α | 171.75Β ααΆα | -3.41% |
ααΆαααα½ααα»αααααΌαααα»α | 50.46Β ααΆα | 5.39% |
ααΌαβααααα»α | 121.29Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 30.12Β ααΆα | β |
ααααααααααΉαααααα
| 4.83 | β |
ααα
ααααααΎαααααα | -59.44% | β |
ααα
ααααααΎααΎααα»α | -80.59% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (EUR) | 2018info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | -166.08Β ααΆα | -12.45% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | -136.62Β ααΆα | -19.51% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -8.64Β ααΆα | -10.30% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 130.68Β ααΆα | 45,590.91% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | -15.11Β ααΆα | 87.26% |
ααα αΌαααΆα
αααααΆααααααα | -72.64Β ααΆα | -18.41% |
α’αααΈ
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
ααΆααααααΎαα‘αΎα
29 ααΈααΆ 2002
αααααβαααααΆα
αα»ααααα·α
117
